Peptides That Improve Gut Motility: A Guide for SIBO

If there is one physiological dysfunction that sits at the heart of most SIBO cases, it is impaired gut motility — specifically, disruption of the migrating motor complex (MMC), the powerful housekeeping wave of contractions that sweeps the small intestine clean between meals. Without adequate MMC activity, bacteria that would normally be swept into the colon are instead allowed to accumulate in the small intestine. This is why addressing motility is not optional in SIBO management; it is foundational. Prokinetic drugs and natural compounds have long been the go-to approach, but a newer category — motility-influencing peptides — is generating substantial research interest. Understanding the peptide biology of gut motility may open new therapeutic options for people who haven't responded adequately to conventional prokinetics.

Why Motility Is the Core Issue in SIBO

The migrating motor complex is a cyclical pattern of electrical and mechanical activity that propagates from the stomach to the terminal ileum approximately every 90 to 120 minutes during the fasting state. It occurs in four phases, with the powerful Phase III contractions — sometimes called the 'intestinal housekeeper' — generating high-amplitude waves that propel luminal contents, including bacteria, in the aborad (toward the colon) direction. Studies using lactulose breath testing and gastric manometry have consistently shown that SIBO patients have reduced MMC frequency, reduced Phase III amplitude, or both.

The causes of MMC disruption are multiple and sometimes overlapping: post-infectious damage to the enteric nervous system (particularly the interstitial cells of Cajal that function as gut pacemakers), prior surgical procedures, hypothyroidism, diabetes, connective tissue disorders, opioid use, and chronic stress all impair MMC function. Crucially, the MMC is regulated in large part by peptide hormones — which is precisely what makes the peptide therapeutics discussed in this article biologically relevant.

Motilin and Its Analogues

Motilin is a 22-amino acid peptide hormone produced by Mo cells in the duodenum and jejunum. It is one of the primary endogenous initiators of MMC Phase III activity. Motilin is released in a cyclical pattern that mirrors the MMC cycle itself, with peak levels occurring just before each Phase III episode. It acts on motilin receptors (also known as GPR38) on smooth muscle cells and enteric neurons of the upper GI tract to trigger the powerful contractions of Phase III. The macrolide antibiotic erythromycin was discovered to be a motilin receptor agonist in the 1980s, which is why it has been used as a prokinetic — though at sub-antibiotic doses — and this discovery sparked significant interest in developing more selective motilin receptor agonists.

Several motilin receptor agonists (motilides) have been developed and tested in clinical trials. Camicinal (GSK962040) reached Phase 2 trials for gastroparesis and showed promising gastric emptying acceleration in early studies. Mitemcinal (GM-611) was evaluated for diabetic gastroparesis. The challenge that has plagued motilide development is tachyphylaxis — rapid downregulation of motilin receptors with repeated dosing, causing loss of efficacy over time. This is a significant practical limitation for chronic use in SIBO prevention. Researchers are exploring pulsatile dosing strategies that mimic the natural cyclical pattern of motilin release as a potential solution.

Ghrelin Mimetics: A Different Path to Motility

Ghrelin is a 28-amino acid peptide produced primarily by X/A-like cells in the gastric fundus. Best known as the 'hunger hormone,' ghrelin has a critical and sometimes overlooked role in gut motility through its action on growth hormone secretagogue receptor 1a (GHSR-1a), which is expressed throughout the GI tract and enteric nervous system. Ghrelin and the MMC are intimately connected: ghrelin levels rise in the late fasting state, helping to trigger Phase III contractions, and fall after eating. Patients with gastroparesis and post-infectious dysmotility often have impaired ghrelin signaling.

Ghrelin mimetics — synthetic peptides and non-peptide compounds that activate GHSR-1a — have been developed as prokinetics with a potentially more favorable tachyphylaxis profile than motilin agonists. Relamorelin (RM-131), a pentapeptide ghrelin analogue, has been the most clinically advanced. In Phase 2 trials for diabetic gastroparesis, relamorelin demonstrated statistically significant acceleration of gastric emptying and reduction in vomiting frequency. Phase 3 trials were conducted but results were mixed, and the compound has not yet achieved FDA approval. Nevertheless, the mechanism remains compelling for SIBO-related dysmotility, and other ghrelin analogues including growth hormone secretagogues like ipamorelin (covered separately in this series) activate the same pathway.

CGRP, Substance P, and Enteric Neuropeptides

Beyond the primary motility hormones, the enteric nervous system uses a diverse array of neuropeptides to coordinate intestinal movement. Calcitonin gene-related peptide (CGRP) and Substance P are two that have received research attention in the context of gut motility and visceral hypersensitivity — both of which are relevant to SIBO.

CGRP is released from sensory neurons in the gut and generally inhibits motility while sensitizing visceral afferent pathways — contributing to the pain and bloating experienced in conditions like IBS and SIBO. CGRP receptor antagonists are being explored as a therapeutic strategy not only for migraine (where they are already approved) but potentially for conditions of gut hypersensitivity. Conversely, Substance P is released from enteric neurons and generally promotes peristalsis through activation of NK1 receptors on smooth muscle and neurons. The balance of CGRP and Substance P signaling influences both the frequency and character of intestinal contractions, and this balance is disrupted in post-infectious gut dysfunction.

Neurotensin, vasoactive intestinal peptide (VIP), and peptide YY (PYY) are other enteric neuropeptides with motility effects that are subjects of ongoing research. PYY, in particular, is released from L-cells in the ileum and colon in response to feeding and serves as an important brake on upper GI transit — the 'ileal brake' mechanism. In some SIBO patients, dysregulation of the ileal brake contributes to altered transit patterns. Peptide YY analogues are in development for conditions including diabetes and obesity, with potential secondary motility applications.

Peptides vs. Traditional Prokinetics

The conventional prokinetics used in SIBO management — low-dose naltrexone (LDN), low-dose erythromycin, metoclopramide, domperidone, prucalopride, and natural compounds like ginger, 5-HTP, and Iberogast — work through a variety of mechanisms including dopamine receptor antagonism, serotonin receptor agonism, opioid receptor modulation, and motilin receptor agonism. Each has advantages and limitations in terms of efficacy, side effect profile, and long-term tolerability.

Research Status and What's Coming

The field of motility peptide therapeutics is advancing, though progress has been slower than hoped due to the challenges of tachyphylaxis, the complexity of GI motility disorders, and regulatory hurdles. Several peptide-based prokinetics are in clinical development. Carmunity biosciences and other companies are pursuing next-generation motilin analogues with modified binding kinetics designed to reduce receptor downregulation. Ghrelin analogue research continues, with several compounds in Phase 2 for gastroparesis.

For the SIBO community specifically, the most promising near-term development may be the recognition by gastroenterologists that motility enhancement should be a cornerstone of SIBO management — not an afterthought. As the evidence base for specific prokinetic strategies grows, we can expect more standardized, evidence-based protocols that combine antimicrobial treatment with motility support in a structured, sequential fashion. The peptide therapeutics described in this article will likely play an increasing role in those protocols as clinical evidence matures.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.